Regeneron convinces PTAB to review Novartis syringe patent

The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

Baker McKenzie strengthens IP bench with new German lead

16 April 2026 Fresh hire, who will take up his new role in May, brings years of expertise in pharmaceuticals and artificial intelligence to the firm’s Frankfurt practice.

Americas

Cancer drug researcher hit with suit over mutation-targeting tools

16 April 2026 The Cambridge biotech is accused of infringing six patents covering technologies used to target drug-resistant cancer mutations.

Big Pharma

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

15 April 2026 The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.

More features

Baker McKenzie strengthens IP bench with new German lead

Cancer drug researcher hit with suit over mutation-targeting tools

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

Court narrows Mylan’s Copaxone suit but key claims survive

IP finance gap risks startup exodus, EUIPO warns

Oracle retaliates with lawsuit to laid-off staff member’s ‘demands’

LSPN Awards USA: Meet the judges

UK patent office adopts EPO standards for AI inventions

Regeneron convinces PTAB to review Novartis syringe patent

More on this story

Editor's picks

Editor's picks

More features